Vaxdyn introduces its multi-pathogen vaccine candidate KapaVax at the World Vaccine Congress Europe

In an oral presentation within the track “AMR & Bacterial Vaccines”, chaired by Dr Jan Poolman (Bacterial Vaccine Discovery and Early Development, Janssen), Dr. Infante showed how Vaxdyn’s technology can deliver endotoxin-free inactivated whole cell vaccines presenting outer-membrane proteins of different bacteria in the surface, therefore raising immunity against different bacteria with only one immunogen. The KapaVax candidate targets include three of the most worrisome antibiotic-resistant bacteria of the list of the WHO: Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii, for which there are not available vaccines yet. The primary target population in need will be individuals affected by chronic lung problems in high risk of developing antibiotic-resistant infections by these bacteria.

The presentation of Dr. Infante was part of a session of pipeline updates by companies funded by the CARB-X organization (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator; carb-x.org), moderated by CARB-X Alliance Director Dr. Ed T. Buurman and with participation of other two institutions of CARB-X’s pipeline, Vaxcyte, presented by Dr. Jeff Fairman (VP of Research), and The Jenner Institute, presented by Dr. Calman MacLennan (Professor of Vaccine Immunology).

Full PR available here